An FDA advisory panel endorsed expanding the approval of Roche Holding's Perjeta, or pertuzumab, to include treatment to reduce tumor size before surgery for early-stage breast cancer. The drug, developed by Roche unit Genentech, is on the market for treatment of metastatic breast cancer. A decision is expected by the end of October.
FDA advisers support use of Perjeta for early-stage breast cancer
SmartBrief Job Listings for Health Care
|Senior Research Analyst||
America's Health Insurance Plans (AHIP)
|Manager, Regulatory Affairs||
|Washington DC, DC|
|Senior Counsel - FDA Regulatory Affairs||
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|